These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 19494719

  • 1. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
    Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L, Serni S, Proietti-Pannunzi L, Fang Y, Jhanwar SC, Orlando C, Carini M, Forti G, Baldi E, Luzzatto L.
    J Endocrinol Invest; 2009 Jul; 32(7):590-6. PubMed ID: 19494719
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [Abstract] [Full Text] [Related]

  • 3. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.
    Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
    [Abstract] [Full Text] [Related]

  • 4. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [Abstract] [Full Text] [Related]

  • 5. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T.
    Clin Cancer Res; 2008 Jun 01; 14(11):3395-400. PubMed ID: 18519769
    [Abstract] [Full Text] [Related]

  • 6. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.
    Mod Pathol; 2008 Feb 01; 21(2):67-75. PubMed ID: 18065961
    [Abstract] [Full Text] [Related]

  • 7. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.
    Neoplasia; 2006 Oct 01; 8(10):885-8. PubMed ID: 17059688
    [Abstract] [Full Text] [Related]

  • 8. ERG rearrangement is present in a subset of transition zone prostatic tumors.
    Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.
    Mod Pathol; 2010 Nov 01; 23(11):1499-506. PubMed ID: 20693982
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.
    Clin Cancer Res; 2009 Jul 15; 15(14):4706-11. PubMed ID: 19584163
    [Abstract] [Full Text] [Related]

  • 10. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.
    Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A.
    Br J Cancer; 2007 Dec 17; 97(12):1690-5. PubMed ID: 17971772
    [Abstract] [Full Text] [Related]

  • 11. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
    Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, Bouzyk M, Seth A, Leyland-Jones B.
    Br J Cancer; 2010 Feb 02; 102(3):570-6. PubMed ID: 20068566
    [Abstract] [Full Text] [Related]

  • 12. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV, Mevs LV, Chashchina LI, Pikul MV, Gryzodub OP, Stakhovsky EO, Kashuba VI.
    Exp Oncol; 2018 Jun 02; 40(2):101-108. PubMed ID: 29949537
    [Abstract] [Full Text] [Related]

  • 13. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.
    Eur Urol; 2011 Nov 02; 60(5):897-904. PubMed ID: 21802835
    [Abstract] [Full Text] [Related]

  • 14. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.
    Lee K, Chae JY, Kwak C, Ku JH, Moon KC.
    Urology; 2010 Nov 02; 76(5):1268.e7-13. PubMed ID: 20800881
    [Abstract] [Full Text] [Related]

  • 15. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR.
    Genes Chromosomes Cancer; 2012 Aug 02; 51(8):781-91. PubMed ID: 22505341
    [Abstract] [Full Text] [Related]

  • 16. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC.
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun 02; 40(6):392-6. PubMed ID: 21914348
    [Abstract] [Full Text] [Related]

  • 17. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A, Dimovski A, Dohcev S, Stavridis S, Stankov O, Saidi S, Gjorgjievska M, Popov Z.
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun 01; 41(1):5-14. PubMed ID: 32573479
    [Abstract] [Full Text] [Related]

  • 18. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
    Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y.
    Tumour Biol; 2016 Sep 01; 37(9):12397-12402. PubMed ID: 27320318
    [Abstract] [Full Text] [Related]

  • 19. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA.
    Cancer Biol Ther; 2009 Jan 01; 8(2):125-30. PubMed ID: 19029822
    [Abstract] [Full Text] [Related]

  • 20. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
    Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA, Transdisciplinary Prostate Cancer Partnership ToPCaP.
    Prostate; 2015 Jun 15; 75(9):897-906. PubMed ID: 25728532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.